Similarly, SPARCL1 was found to be a tumor suppressor in gastric cancer (Li et al., 2012), osteosarcoma (Zhao et al., 2018b), pancreatic cancer (Esposito et al., 2007), lung cancer (Deng et al., 2021), and renal cell carcinoma (Ye et al., 2017). Here, SPARCL1 is linked to lung cancer.